合一生技股份有限公司
合一生技股份有限公司為研發型生技公司,核心產品為自行研發之糖尿病足潰瘍(DFU)新藥「速必一(Fespixon)」。公司同時開發多項針對異位性皮膚炎、氣喘及抗感染之創新抗體藥物。公司成立於 2008 年,總部位於台灣台北。
今日上漲 4.07%,股價站回短期均線。該股 RSI(6) 為 62.6,處於中性區間,短線無明顯超買超賣訊號。股價站上5日、20日均線,跌破60日、120日均線。短中期均線呈空頭排列,趨勢偏空。KD 指標中性(K=74.1);MACD 柱狀體為正值,維持多方動能。 (自動產生 · 非投資建議)
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-11 | +821 | 0 | +10 | +828 |
| 08-10 | -15 | 0 | +8 | -11 |
| 08-07 | +183 | 0 | +24 | +199 |
| 08-06 | -182 | 0 | +29 | -191 |
| 08-05 | -469 | 0 | +18 | -480 |
| 08-04 | +341 | 0 | +28 | +353 |
| 08-03 | -121 | 0 | +41 | -134 |
| 07-31 | -369 | 0 | +22 | -381 |
| 07-30 | -670 | 0 | +66 | -666 |
| 07-29 | +578 | 0 | +87 | +568 |
| 07-28 | -273 | 0 | +120 | -293 |
| 07-27 | -122 | 0 | +32 | -125 |
| 07-24 | -1,680 | 0 | +142 | -1,683 |
| 07-23 | -320 | 0 | +17 | -324 |
| 07-22 | -1,050 | 0 | +26 | -1,047 |
| 07-21 | -844 | 0 | +29 | -829 |
| 07-20 | -177 | 0 | +30 | -165 |
| 07-17 | -1,078 | 0 | +42 | -1,078 |
| 07-16 | -172 | 0 | +12 | -168 |
| 07-15 | -15 | 0 | +43 | -3 |
| 07-14 | -72 | 0 | +46 | -72 |
| 07-13 | -1,279 | 0 | +60 | -1,301 |
| 07-09 | -271 | 0 | +30 | -268 |
| 07-08 | -1,366 | 0 | +49 | -1,368 |
| 07-07 | -159 | 0 | +45 | -174 |
| 07-06 | +968 | 0 | +117 | +963 |
| 07-03 | +5,250 | 0 | +156 | +5,305 |
| 07-02 | -792 | 0 | +15 | -802 |
| 07-01 | +537 | 0 | +20 | +539 |
| 06-30 | +666 | 0 | +15 | +664 |
| 06-29 | +1,310 | 0 | +18 | +1,314 |
| 06-26 | -966 | 0 | +42 | -983 |
| 06-25 | +295 | 0 | +34 | +297 |
| 06-24 | +542 | 0 | +11 | +541 |
| 06-23 | +544 | 0 | +15 | +544 |
| 06-22 | +141 | 0 | +1 | +141 |
| 06-18 | +227 | 0 | +17 | +228 |
| 06-17 | -24 | 0 | +40 | -24 |
| 06-16 | -819 | 0 | +52 | -821 |
| 06-15 | +145 | 0 | +17 | +145 |
| 06-12 | +390 | 0 | +13 | +356 |
| 06-11 | -432 | 0 | +56 | -475 |
| 06-10 | -267 | 0 | +36 | -251 |
| 06-09 | -389 | 0 | +15 | -390 |
| 06-08 | +13 | 0 | +13 | -8 |
| 06-05 | +127 | 0 | +7 | +125 |
| 06-04 | +227 | 0 | +14 | +227 |
| 06-03 | -763 | 0 | +43 | -761 |
| 06-02 | +188 | 0 | +10 | +189 |
| 06-01 | +317 | 0 | +29 | +317 |
| 05-29 | +351 | 0 | +11 | +354 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 2166 萬 | +50.6% | +101.8% |
| 2026/03 | 1438 萬 | +51.9% | +128.8% |
| 2026/02 | 946 萬 | -25.9% | -15.9% |
| 2026/01 | 1278 萬 | -58.3% | +66.5% |
| 2025/12 | 3062 萬 | +273.1% | +169.8% |
| 2025/11 | 821 萬 | +87.6% | -13.5% |
| 2025/10 | 437 萬 | -36.9% | -58.6% |
| 2025/09 | 693 萬 | -29.0% | -35.6% |
| 2025/08 | 976 萬 | -43.8% | -11.3% |
| 2025/07 | 1737 萬 | +109.8% | +130.5% |
| 2025/06 | 828 萬 | +8.3% | -32.1% |
| 2025/05 | 764 萬 | - | +3.1% |